Broad Clinical Labs (BCL) is a subsidiary of the Broad Institute of MIT and Harvard that provides a range of research and clinical services — including CAP-accredited and CLIA-certified genomic data generation and advanced genomic analysis — both for the Broad research community and for the rest of the world.
BCL is comprised of ~240 people with expertise in a range of disciplines including
Broad Clinical Labs (BCL) has evolved from the Broad Institute’s Genomics Platform (GP), which has a 30-year track record of delivering on transformative projects in the field of genomics. Throughout our history we have created foundational genomics resources and capabilities for the community and undertaken large-scale disease-based projects that pioneer approaches and advance the understanding of the genomic basis of disease and other traits.
Since the inception of the Human Genome Project in the 1990s, we have played a leadership role in the design, data generation, and methods development in support of major genomic resource projects including:
Generation of Comparative Reference Genomes (many)
Over the past ten years, we have been the largest producer of human genomic information in the world, and during the SARS-CoV-2 pandemic were one of the largest producers of COVID-19 diagnostic test results in the world. Since 2022, we have routinely generated >2,000 terabases per month of genomic data — a rate equivalent to one whole human whole genome every three minutes. We have processed more than 3 million genomic specimens (including >550k genomes and >770k exomes) from more than 1,400 groups in more than 50 countries.
Since 2022, we have processed over half a million genomic specimens from around the world , which were processed through workflows including whole genome and whole exome sequencing, RNA sequencing, genotyping, Covid sequencing, and many others including cancer panel sequencing, single cell sequencing, and non-Covid microbial sequencing. The data generated and projects supported by data generation from these specimens are destined to contribute knowledge to a wide array of fields, from rare disease research to population genomics, from cancer clinical trials to understanding cell circuitry.